relugolix
pfizer
['hero', 'prostate', '5073', 'pfizer']
at #asco22, see a phase 3 hero study subgroup analysis of body mass index on efficacy &amp; safety of a gnrh receptor antagonist and an lhrh agonist in men with advanced #prostatecancer #5073 
Dedicated to communicating emerging science from Pfizer Oncology. Please see our community guidelines: https://t.co/MU3blmItSZ